DAYTRAL BROWN: Open Payments
NPI 1154629798 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$221 in 10 payments from 7 companies in 2025. Trend: 2023 $164 · 2024 $87 · 2025 $221
Food & beverage: $221
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $69 |
| ABBVIE INC. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $17 |
Products named: Ozempic, VRAYLAR, FARXIGA, CAPLYTA, Quviviq, SPRAVATO, MOUNJARO.
Industry payments across TX — which companies pay providers there.
